Scancell Holdings PLC (LSE:SCLP) - Share price - Overview


Stock Report

Scancell Holdings PLC SCLP

Last Price
GBX5.15

Day Change
0.00|0.00%

As of 16/04/2019
16:28:18 BST | GBX
Minimum 15 Minutes Delay.

Last Close5.15p
Day Range5.00 - 5.00
Mkt Cap-
52-Wk Range5.00 - 15.43
Yield %-
ISINGB00B63D3314
Volume100,000
P/E-3.84
P/S-
P/CF-0.04

Share Price

Total Returns 22/04/2019

 Chg (%)  
More ...
Scancell Holdings PLC-8.04 
FTSE 100 TR GBP2.67
 
Financials
201620172018
More ...
Income Statement
Turnover---
Operating Profit-3.04-4.55-4.94
Net Profit-2.58-3.55-4.20
Reported EPS-1.14-1.36-1.34
Balance Sheet
Current Assets7.093.5211.15
Non Current Assets3.483.513.49
Total Assets10.577.0314.64
Current Liabilities0.580.530.70
Total Liabilities---
Total Equity9.996.5013.94
Cash Flow
Operating Cash Flow-3.00-4.49-4.81
Net Change in Cash3.47-3.867.63

Regulatory News

DateAuthor Headline
14/03/2014Emma Wall Taxman Cancels Benefits on VCT
As one venture capital trust loses its tax efficient status we examine what makes a VCT and how you can use them to reduce your tax liability before April 5
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
25/07/2018PurchaseDr. John Chiplin11.702,483291.00
24/07/2018SaleDr. John Chiplin11.002,483273.00
09/05/2018PurchaseMs. Katherine Cornish-Bowden12.0010,9281,311.00
09/05/2018PurchaseDr. Sally Elizabeth Adams12.003,095371.00

Company Profile

Scancell Holdings PLC is a biopharmaceutical company focused on the cancer therapeutics market. The company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 25/09/2019

Final Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-35.45
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Executive DirectorProfessor Linda Gillian Durrant
Executive DirectorDr Richard Morley Goodfellow
Non-Executive DirectorDr Matthew Gerrard Winston Frohn
Executive Director, ChairmanDr. John Chiplin
Executive Director, Development DirectorDr. Sally Elizabeth Adams
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.